T: +30 26510 99657

Αιματολογική Κλινική - Π.Γ.Ν. Ιωαννίνων

Ερευνητικό Αιματολογικό Εργαστήριο

Κλινικό Έργο

Ερευνητικό Αιματολογικό Εργαστήριο

Το Ερευνητικό Αιματολογικό Εργαστήριο είναι επιφορτισμένο με τη διενέργεια εξειδικευμένων μοριακών αναλύσεων όπως π.χ. μεταλλάξεων γονιδιών που σχετίζονται με αιματολογικές νεοπλασίες, με τη διαχείριση βιολογικού υλικού (Biobanking) που δωρίζεται για ερευνητικούς σκοπούς και με την άσκηση τελειόφοιτων του τμήματος ΒΕΤ του ΠΙ στην εφαρμογή μοριακών τεχνικών. Το Εργαστήριο υποστηρίζει τη μεταφραστική έρευνα της Αιματολογικής Κλινικής.

Δημοσιεύσεις
Παρακάτω μπορείτε να δείτε τις δημοσιεύσεις του Ερευνητικού Αιματολογικού Εργαστηρίου
  1. Koumpis E, Tassi I, Malea T, Papathanasiou K, Papakonstantinou I, Serpanou A, Tsolas E, Kapsali E, Vassilakopoulos TP, Papoudou-Bai A, Hatzimichael E. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome. Pathol Res Pract. 2021 Jul 28;225:153567. doi: 10.1016/j.prp.2021.153567. Online ahead of print.
  2. Hatzimichael E, Murray S, Briasoulis E. Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström’s macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias. Am J Blood Res. 2013
  3. Hatzimichael E, Dasoula A, Kounnis V, Benetatos L, Nigro CL, Lattanzio L, Papoudou-Bai A, Dranitsaris G, Briasoulis E, Crook T. Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implica-tions. Leuk Lymphoma 2012
  4. Hatzimichael E, Dasoula A, Shah R, Syed N, Papoudou-Bai A, Coley HM, Dranitsaris G, Bourantas KL, Stebbing J, Crook T. The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. Eur J Haematol 2010;84:47-5
  5. Hatzimichael E, Dasoula A, Benetatos L, Syed N, Dranitsaris G, Crook T, Bourantas K. Study of specific genetic and epigenetic variables in multiple myeloma. Leuk Lymphoma 2010;51:2270-2274.
  6. Hatzimichael E, Dranitsaris G, Dasoula A, Benetatos L, Stebbing J, Crook T, Bourantas KL. Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. Clin Lymphoma Myeloma 2009;9:239-242.
  7. Hatzimichael E, Benetatos L, Dasoula A, Dranitsaris G, Tsiara S, Georgiou I, Syrrou M, Stebbing J, Coley HM, Crook T, Bourantas KL. Absence of methylation-dependent tran-scriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG is-land in plasma cell neoplasia. Leuk Res 2009;33:1272-1275.
  8. Hatzimichael E, Dasoula A, Benetatos L, Makis A, Stebbing J, Crook T, Syrrou M, Bourantas KL. The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms. Br J Haematol 2008;141:557-558.
  9. Benetatos L, Dasoula A, Hatzimichael E, Georgiou I, Syrrou M, Bourantas KL. Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clin Lymphoma Myeloma 2008;8:171-175
  1. Benetatos L, Dasoula A, Hatzimichael E, Syed N, Voukelatou M, Dranitsaris G, Bourantas KL, Crook T. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. Ann Hematol 2011;90:1037-1045.
  2. Benetatos L, Hatzimichael E, Dasoula A, Dranitsaris G, Tsiara S, Syrrou M, Georgiou I, Bourantas KL. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res 2010;34:148-153
  3. Benetatos L, Dasoula A, Syed N, Hatzimichael E, Crook T, Bourantas KL. Methylation anal-ysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syn-dromes. Leukemia 2008;22:1293-1295
  1. Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJ, Karran LE, ElguetaKarstegl C, Farrell PJ, Thompson A, Briasoulis E, Crook T. The colla-gen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. Br J Cancer. 2012 Oct 9;107(8):1423-32.
  2. Lee S, Syed N, Taylor J, Smith P, Griffin B, Baens M, Bai M, Bourantas K, Stebbing J, Naresh K, Nelson M, Tuthill M, Bower M, Hatzimichael E, Crook T. DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt’s lymphoma. Br J Cancer 2010;103:265-274.

ραντεβού για Εξωτερικά Ιατρεία

Τ: +302651099504 -505

elGreek
en_USEnglish elGreek